Evidence map›Paper›PMID 35745646›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation.

Stefania Lama, Amalia Luce, Giuseppe Bitti, Pilar Chacon-Millan, Annalisa Itro, Pasquale Ferranti, Giovanni D'Auria, Marcella Cammarota, Giovanni Francesco Nicoletti, Giuseppe Andrea Ferraro and 4 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Multi-Anticancer Activities of Phytoestrogens in Human Osteosarcoma.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Stefania LamaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0002-9972-1291
Amalia LuceDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0003-0372-6870
Giuseppe BittiInstitute of Biophysics, 2nd Faculty of Medicine, Charles University, V Uvalu 84, 15006 Prague, Czech Republic.
Pilar Chacon-MillanDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Annalisa ItroPlastic Surgery Unit, Department of Multidisciplinary Medical and Dental Specialties, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Pasquale FerrantiDepartment of Agricultural Sciences, University of Naples Federico II, 80138 Portici, Italy.
Giovanni D'AuriaDepartment of Agricultural Sciences, University of Naples Federico II, 80138 Portici, Italy.ORCID 0000-0002-9386-3256
Marcella CammarotaDepartment of Experimental Medicine, Section of Biotechnology, Molecular Medicine and Medical Histology, University of Campania "L. Vanvitelli", 80138 Naples, Italy.
Giovanni Francesco NicolettiPlastic Surgery Unit, Department of Multidisciplinary Medical and Dental Specialties, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Giuseppe Andrea FerraroPlastic Surgery Unit, Department of Multidisciplinary Medical and Dental Specialties, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Chiara SchiraldiDepartment of Experimental Medicine, Section of Biotechnology, Molecular Medicine and Medical Histology, University of Campania "L. Vanvitelli", 80138 Naples, Italy.ORCID 0000-0002-1066-843X
Michele CaragliaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0003-2408-6091
Evzen AmlerInstitute of Biophysics, 2nd Faculty of Medicine, Charles University, V Uvalu 84, 15006 Prague, Czech Republic.
Paola StiusoDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0001-5096-7488
University of Campania "Luigi Vanvitelli" · ITCharles University · CZFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycaprolactone nanofibers are used as scaffolds in the field of tissue engineering for tissue regeneration or drug delivery. Polycaprolactone (PCL) is a biodegradable hydrophobic polyester used to obtain implantable nanostructures, which are clinically applicable due to their biological safety. Polydatin (PD), a glycosidic precursor of resveratrol, is known for its antioxidant, antitumor, antiosteoporotic, and bone regeneration activities. We aimed to use the osteogenic capacity of polydatin to create a biomimetic innovative and patented scaffold consisting of PCL-PD for bone tissue engineering. Both osteosarcoma cells (Saos-2) and mesenchymal stem cells (MSCs) were used to test the in vitro cytocompatibility of the PD-PCL scaffold. Reverse-phase (RP) HPLC was used to evaluate the timing release of PD from the PCL-PD nanofibers and the MTT assay, scanning electron microscopy, and alkaline phosphatase (ALP) activity were used to evaluate the proliferation, adhesion, and cellular differentiation in both osteosarcoma and human mesenchymal stem cells (MSCs) seeded on PD-PCL nanofibers. The proliferation of osteosarcoma cells (Saos-2) on the PD-PCL scaffold decreased when compared to cells grown on PLC nanofibers, whereas the proliferation of MSCs was comparable in both PCL and PD-PCL nanofibers. Noteworthy, after 14 days, the ALP activity was higher in both Saos-2 cells and MSCs cultivated on PD-PCL than on empty scaffolds. Moreover, the same cells showed a spindle-shaped morphology after 14 days when grown on PD-PCL as shown by SEM. In conclusion, we provide evidence that nanofibers appropriately coated with PD support the adhesion and promote the osteogenic differentiation of both human osteosarcoma cells and MSCs.

Indexed as

mesenchymal stem cellsosteogenic differentiationosteosarcomapolycaprolactone nanofiberspolydatin

Identifiers

PMID35745646
PMCPMC9230847
OpenAlexW4282841003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.